Clinical Trials Logo

Peripheral Neuropathy clinical trials

View clinical trials related to Peripheral Neuropathy.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05595109 Enrolling by invitation - Breast Cancer Clinical Trials

Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

Start date: October 28, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Aim of the work This study aims to evaluate the possible beneficial role of silymarin in attenuating both doxorubicin related cardiac and hepatic toxicities and paclitaxel associated peripheral neuropathy and improving cognitive impairment in patients with breast cancer. This study will be a randomized placebo controlled parallel study. The study will be performed in accordance with the ethical standards of Helsinki declaration in 1964 and its later amendments. Group one: (Placebo group; n=28) which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day) followed by 12 cycles of paclitaxel (each cycle was given in a weekly basis) plus placebo tablets once daily. Group two: (Silymarin group; n=28) which will receive the same regimen plus silymarin 140mg once daily

NCT ID: NCT02428101 Enrolling by invitation - Clinical trials for Peripheral Neuropathy

Oxaliplatin - Induced Peripheral Neuropathy in Patients With Gastrointestinal Tract Cancer

Start date: November 2014
Phase:
Study type: Observational

This study will examine DNA from Gastrointestinal Tract of cancer patients treated with oxaliplatin to look for a variation (mutation) of the ABCG2 gene that may lead to drug-induced peripheral neuropathy in certain patients. The DNA will be extracted from patients' blood samples and are analyzed for the ABCG2 single nucleotide polymorphism (G34A - rs2231137 and A/A -rs3114018 genotypes) and correlated with peripheral neuropathy grades.